A Randomized Controlled Trial Comparing 7 day Vonoprazan based Triple Therapy and 14 day Omeprazole based Triple Therapy for Helicobacter pylori Infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210130003

Enrollment

120

Registered

2021-01-30

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. Pylori infection Helicobacter pylori treatment, vonoprazan based triple therapy, omeprazole based triple therapy

Interventions

Vonoprazan 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500 mg bid for 7 days,Omeprazole 20mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days

Active Comparator Drug,Placebo Comparator Drug

7 day vonoprazan based triple therapy,14 day omeprazole based triple therapy

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Present of H. Pylori: confirm by one or more of the following methods - Urea breath test - Rapid urease test or - Histology 2. Patient agree to joint the project

Exclusion criteria

Exclusion criteria: 1. History of allergy to PPI, vonoprazan, penicillin, clarithromycin 2. Previous H. Pylori eradication therapy 3. History of antibiotic to effect h. Pylori treatment before 1 month 4. History of GI malignancy or surgery 5. Serious cardiovascular, pulmonary, renal, hepatic disorder or malignancy 6. Pregnancy or lactating 7. History of drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
Eradication rates of H. Pylori infection 6 week Chi-square	—

Secondary

Measure	Time frame
Adverse event of H. Pylori treatment 3 and 14 day Chi-square	—

Countries

Thailand

Contacts

Public ContactArunluk Buranathawornsom

Medical research

Arunluk2530@gmail.com0894746825

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026